SAN DIEGO, May 4, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today a poster titled, "Updated analyses of randomized, double-blind, Phase 3 study of Femprox®, an alprostadil cream with a novel transdermal delivery technology for the treatment of female sexual arousal disorder (FSAD)," will be presented as a moderated poster (#1498) at the American Urological Association Annual Meeting which is being held May 19-23, 2012 in Atlanta, GA.
